Global Cholera Vaccine Market 2026 – 2035

The market size of the global cholera vaccine will be estimated at USD 312 million in 2025 and is expected to grow between USD 336 million in 2026 and about USD 649 million by 2035 with a current CAGR of 7.6% during the period of 2026 to 2035.

The cholera vaccines market is mainly influenced by the increased number of cholera outbreaks, particularly in low-and middle-income countries where lack of sanitation, unsafe drinking water, rapid urbanization, and humanitarian crises make diseases likely to occur. The effects of climate change, such as floods and cyclones, also make the situation worse and hence there is a greater need for quick and preventive vaccinations.

Demand has been substantially increased by the strong support from governments and global health organizations such as the World Health Organization, Gavi, the Vaccine Alliance, and UNICEF through mass vaccination campaigns, emergency stockpiles, and subsidized vaccine procurement.

Market Highlight

• North America had a market share of 38% and was the market leader in the cholera vaccine market in 2025.

• It is projected to have the highest growth rate across Asia Pacific in the years 2026-2035.

• By type, the Killed Oral O1 and O139 segment dominates the market with over 58% in 2025.

• By distribution channel, the hospital pharmacy held the largest revenue share of 45% in 2025.

Significant Growth Factors

The cholera vaccine market trends present significant growth opportunities due to several factors:

• Growth in Preventive Healthcare Awareness:

Preventive healthcare awareness is one of the primary factors driving the cholera vaccine market, as different parties involved in the process such as governments, healthcare providers, and communities are slowly but surely acknowledging vaccination as a cost-effective way of preventing outbreaks rather than just treating them and emergency response. World Health Organization and Gavi public health education campaigns have played a vital role in disseminating information about the transmission of cholera and the significance of immunization in vulnerable populations.

In the areas most affected by cholera, among the people living in the worst urban conditions, in refugee camps, and in places that lack clean water and sanitation, the awareness about vaccination is the strongest. In these places, vaccination is regarded as a necessity in order to stop the disease from spreading and causing death. Besides, the awareness among international travelers, humanitarian workers, and medical personnel has been rising and this has created a demand for oral cholera vaccines which are considered a preventive measure, thus supporting the global market for cholera vaccines and its sustainable growth.

• Growing prevalence of cholera:

The cholera vaccine market is mainly driven by the rising incidence of cholera, as continuous outbreaks are still a major health hazard, especially in places with poor sanitation, no safe drinking water, and fragile health systems. The resurgence of cholera in specific areas of Africa, South Asia, and the Middle East has led governments and health agencies to treat vaccination as the most important preventive and outbreak-control measure. Through the WHO, guidance, and surveillance activities the increasing occurrence and magnitude of cholera outbreaks have been factors that have bolstered the need for both reactive and preventive immunization campaigns. Moreover, the war is a cause of displacement of people, and urban overcrowding and climate-related flooding causing natural disasters are also contributing to cholera spreading. Thus, the demand for oral cholera vaccines will quickly go up. Vaccination is increasingly regarded as a necessary requirement to reduce the disease burden, control outbreaks, and save lives in cholera-prone and high-risk areas.

The above factors are among the reasons why the cholera vaccine market is experiencing continuous growth. For instance, the World Health Organization (WHO), outputting its annual cholera figures for 2024, has raised the alarm in the world community, the figures showing an enlarging trend both in sickness and death from this disease. Cases of cholera went up by 5% and deaths by 50% in 2024 when compared to 2023, with over 6000 people losing their lives to a disease that can be both prevented and treated. Although these figures are alarming in their own right, they are actually less than the actual burden of cholera.

What are the Major Advances Changing the Cholera Vaccine Market Today?

• Next-Generation Vaccines and Clinical Trials:

Next-generation vaccines and clinical trials in the cholera vaccine market imply the ongoing process of the development and evaluation of cutting-edge vaccine candidates, which are aimed to enhance protection, simplify dosing, and keep up with global demand that goes way beyond the current incumbent oral cholera vaccines. Among the innovations in this area are those vaccines with the potential to provide longer immunity and thus be more effective especially for babies, single-dose use, and better quality for the low-resource settings due to their stability.

A number of next-generation candidates are moving through the trials, most notably Hillchol, which is being developed by Bharat Biotech and showcasing very good safety and immunogenicity in the late trials thus aiding the efforts to solve the global vaccine shortage problem. In parallel, the International Vaccine Institute, by using the conjugate and developing novel oral formulations, is targeting the very young ones and the whole community for immunization, respectively, thus assuring protection and keeping immunity in the society for a longer time. These clinical trials, which are most often done in the cholera-endemic areas under the supervision of international regulators, are no longer contributing only to the improvement of vaccines but also letting the market benefit from the increased diversity of production and the global preparedness for cholera outbreak in future thus strengthening it.

• New Vaccine Formats with Improved Delivery:

The term "new vaccine formats with better delivery in the cholera vaccine market denotes novel formulations that are aimed to provide vaccination in a more comfortable, quicker, and practical way in places with a shortage of resources and outbreaks. Simplified oral vaccines, dry or capsule-based formulations, and more thermostable vaccines are among the new delivery methods that lessen dependence on intricate cold-chain logistics and healthcare personnel that are trained. One such example is the simplified oral vaccine Euvichol-S that can be manufactured very quickly and deployed easily on a large scale in emergencies, while the dry vaccines that are under study are targeted to storage and transportation ease in remote areas. The International Vaccine Institute is one of the research organizations that are helping these new ones come up with cholera vaccines and focusing mainly on getting the coverage and distribution done in the endemic areas. The new vaccine formats can easily be administered, they have fewer storage problems, and their distribution is very efficient so, they are powering up the outbreak response capabilities considerably and consequently the cholera vaccine market is growing due to this.

Category Wise Insights

By Type

Why Killed Oral O1 and O139 Lead the Market?

The Killed Oral O1 and O139 segment dominates the market with over 58% in 2025. The growth of the segment can be attributed to the fact that these vaccines are safe, cover a large number of serotypes, come in oral delivery format, and are used globally. Among the vaccines are Shanchol, Euvichol, and Euvichol-Plus, which include inactivated strains of Vibrio cholerae O1 and O139 — the two serogroups that cause the majority of cholera epidemics — and have been prequalified and recommended by the World Health Organization for use in public health programs worldwide. Their large-scale use in mass immunization and outbreak response campaigns in Africa, Asia, and other endemic areas has been a key factor in the segment's market dominance.

The Whole Cell v. Cholerae O1 with Recombinant B- subunit segment is expected to grow at the highest CAGR over the projected period. The revenue expansion of the vaccine segment is significantly impacted by the already granted regulatory approvals, the acceptance in health programs, and the attractiveness of international tourists, thus enabling sales to be consistently done through public and private means. Its extensive usage history and WHO prequalification have gained the trust of health authorities and procurement agencies, thus making it easier to maintain the application of the vaccine, especially in areas where cholera is considered a threat and where vaccination is given priority.

By Distribution Channel

Why Hospital Pharmacy Dominates the Cholera Vaccine Market?

The hospital pharmacy held the largest revenue share of 45% in 2025. Hospital pharmacies play a vital role in travel medicine where people going to cholera-endemic regions get oral vaccines such as Dukoral or Vaxchora and also immunocompromised or chronic disease patients who may be recommended to vaccinate before exposure. The increasing awareness of preventive healthcare among patients and healthcare providers has led to a rise in demand for cholera vaccines through hospital pharmacies which has been a major factor in the constant revenue growth in this segment.

The retail pharmacy segment is expected to grow at the highest rate over the projected period. Practical collaborations of vaccine producers and pharmacy networks together with expanded insurance coverage for vaccinations in many areas have given a boost to the sales of vaccines in retail pharmacies. The rise in demand for vaccinations, the establishment of pharmacies as healthcare providers with the trust of the consumer, and the growing acceptance of pharmacies as the point of healthcare have all impacted the retailers' revenue contributions within the overall profit of the cholera vaccine market positively.

Report Scope

Regional Analysis

How Big is the North America Cholera Vaccine Market Size?

Its market size, in terms of the North American cholera vaccine, is projected to be USD 118 million in 2025 with a growth of about USD 230 million in 2035 with a CAGR of 6.9% between 2026 and 2035.

Why did North America Dominate the Cholera Vaccine Market in 2025?

In 2025, North America will dominate the global market with an estimated market share of 38%. International travel and preventive health practices mainly accounted for this growth, especially in the United States and Canada, where travelers to cholera-endemic areas are widely vaccinated with Vaxchora—the only FDA-approved oral cholera vaccine. The rise in international travel brings about the increase in the number of people visiting travel clinics and pharmacies for cholera vaccinations to secure their safety from infections, thus directly leading to the rise in vaccine sales and revenue for the region.

U.S. Cholera Vaccine Market Trends

The US is expected to lead the cholera vaccine market over the analysis period. The country's growth is owing to the high prevalence rate of cholera. Moreover, the growing product launch and existence of vaccine manufacturers in the country. Further, growing clinical trials are increasing the market penetration rate.

Why is Asia Pacific Experiencing the Fastest Growth in the Cholera Vaccine Market?

The Asia Pacific region is expected to grow at the highest CAGR during the projected period. In the Asia Pacific area, the cholera vaccine market has seen great growth in terms of revenue due to several interconnected factors that signify both public health requirements and advancing vaccine access. The region is extremely prone to cholera as the majority of the countries like India, Bangladesh, Myanmar, Nepal and Vietnam, besides other countries, experience regular outbreaks caused by high population density, quick sanitation, unsafe water and climate change. This situation demands effective vaccination programs that can be supported by the government and authorities' large-scale immunization and preventive vaccination campaigns along with the help of international health organizations and multilateral funding. These activities increase routine vaccination usage and therefore contribute to the growth of the region's vaccine market revenues by directly stimulating procurement.

China Cholera Vaccine Market Trends

The China market has an extremely fast-growing market. The increase can be attributed to people's awareness regarding the potential health risks and preventive methods. The government has made a commitment to strengthening the health system and disease-proofing technology, which in turn has helped make vaccination clear and easy. One example is Zambia, which has partnered with China to set up the first cholera Production Plant in South Africa by 2024. The whole plan is worth USD 37 million, and the family of three hundred million doses will be bestowed through a combination of Company X and Jijia International Medical Technology Corporation. Hence, all these factors are making the cholera vaccine market in China bigger and bigger.

Why is Europe is growing at a significant rate in the Cholera Vaccine Market?

The cholera vaccines market in Europe has been continually and gradually increasing in terms of revenue, primarily due to the region's non-endemic status for cholera, but still, increasing preventive health measures, travel-related demand, and fortified public health preparedness strategies are contributing as the main drivers of the market. The demand for oral cholera vaccines and the generation of revenue from the commercial side are being positively affected by European citizens traveling to cholera-endemic countries for leisure, business, humanitarian activities, or research who are increasingly getting vaccinated at clinics and pharmacies before their trip.

UK Cholera Vaccine Market Trends

In 2025, the UK Cholera Vaccine industry took a considerable market share. The factor responsible for the growth of the market is the high public awareness level together with the healthcare infrastructure, which brings travel vaccinations nearer to the public through the National Health Service (NHS) and private providers as well as by unambiguous suggestions from travel health authorities. Many UK holidaymakers go to travel clinics before going overseas, where cholera vaccinations along with other recommended immunizations are given, thus causing an increase in the number of people receiving the vaccine.

Why is the Middle East & Africa Region is growing rapidly in the Cholera Vaccine?

The cholera vaccine market in the Middle East and Africa (MEA) region has experienced remarkable growth in revenue primarily because cholera continues to be a major public health issue in many of the countries in the region. Epidemics due to the absence of safe water, inadequate sanitation, natural calamities like floods, and armed conflicts have kept the disease burden high in places like Sudan, South Sudan, and Zambia that are located in the middle of these conflicts, thus causing uninterrupted demand for vaccines that are applied in both outbreak control and preventive campaigns.

UAE Cholera Vaccine Market Trends

UAE is growing rapidly over the projected period. The growth of the cholera vaccine market in the UAE is due to travel-related demand and preventive health emphasis.

Top Players in the Cholera Vaccine Market and Their Offerings

• Sanofi S.A.

• Hilleman Laboratories

• Biological E.

• Celldex Therapeutics

• EuBiologics

• GlaxoSmithKline

• Bharat Biotech

• Pfizer

• Bavarian Nordic A/S

• Shanghai United Cell Biotechnology Co. Ltd.

• Shantha Biotechnics

• Valneva Sweden AB

• Others

Key Developments

Cholera vaccine market has experienced considerable changes in the last two years as the market players are trying to diversify their technological aspects and develop product portfolios using strategic approaches.

• In November 2025: South Africa wants to be the very first African country to produce a cholera vaccine with the commencement this week of a clinical trial on an oral vaccine created by the local firm Biovac. The creation of the vaccine candidate was made possible through a technology transfer collaboration between Biovac and the International Vaccine Institute in South Korea in 2022. (Source: https://healthpolicy-watch.news/south-africa-launches-trial-of-first-african-made-cholera-vaccine/)

These strategic measures have enabled the companies to reinforce their competitive positions, increase the product line, boost their technological competencies, and also seize growth opportunities in the fast-growing cholera vaccine market.

The Cholera Vaccine Market is segmented as follows:

By Type

• Whole Cell v. Cholerae O1 with Recombinant B- subunit

• Killed Oral O1 and O139

By Product

• Vaxchora

• Shanchol

• Dukoral

• Others

By Distribution Channel

• Retail Pharmacy

• Hospital Pharmacy

• Others

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America